WO2020008489A3 - Aptamers for use in the therapy, prevention, diagnosis and detection of the papillomavirus - Google Patents

Aptamers for use in the therapy, prevention, diagnosis and detection of the papillomavirus Download PDF

Info

Publication number
WO2020008489A3
WO2020008489A3 PCT/IT2019/050159 IT2019050159W WO2020008489A3 WO 2020008489 A3 WO2020008489 A3 WO 2020008489A3 IT 2019050159 W IT2019050159 W IT 2019050159W WO 2020008489 A3 WO2020008489 A3 WO 2020008489A3
Authority
WO
WIPO (PCT)
Prior art keywords
papillomavirus
aptamers
diagnosis
therapy
prevention
Prior art date
Application number
PCT/IT2019/050159
Other languages
French (fr)
Other versions
WO2020008489A2 (en
Inventor
Rudy IPPODRINO
Bruna MARINI
Martina BERTOCCO
Original Assignee
Ulisse Biomed S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ulisse Biomed S.R.L. filed Critical Ulisse Biomed S.R.L.
Priority to EP19750180.2A priority Critical patent/EP3818160A2/en
Publication of WO2020008489A2 publication Critical patent/WO2020008489A2/en
Publication of WO2020008489A3 publication Critical patent/WO2020008489A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers

Abstract

Aptamers for use in the therapy, prevention, diagnosis and detection of the Papillomavirus.
PCT/IT2019/050159 2018-07-06 2019-07-05 Aptamers for use in the therapy, prevention, diagnosis and detection of the papillomavirus WO2020008489A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP19750180.2A EP3818160A2 (en) 2018-07-06 2019-07-05 Aptamers for use in the therapy, prevention, diagnosis and detection of the papillomavirus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102018000007017A IT201800007017A1 (en) 2018-07-06 2018-07-06 APTAMERI FOR USE IN PAPILLOMAVIRUS THERAPY, PREVENTION, DIAGNOSIS AND DETECTION
IT102018000007017 2018-07-06

Publications (2)

Publication Number Publication Date
WO2020008489A2 WO2020008489A2 (en) 2020-01-09
WO2020008489A3 true WO2020008489A3 (en) 2020-02-13

Family

ID=63834386

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT2019/050159 WO2020008489A2 (en) 2018-07-06 2019-07-05 Aptamers for use in the therapy, prevention, diagnosis and detection of the papillomavirus

Country Status (3)

Country Link
EP (1) EP3818160A2 (en)
IT (1) IT201800007017A1 (en)
WO (1) WO2020008489A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113481205B (en) * 2021-07-30 2023-11-03 杭州凡泰生物科技有限公司 Aptamer HPV1801 of HPV18 virus particle and application thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DIANA GABRIELA VALENCIA-RESÉNDIZ ET AL: "Inhibition of Human Papillomavirus Type 16 Infection Using an RNA Aptamer", NUCLEIC ACID THERAPEUTICS, vol. 28, no. 2, 1 April 2018 (2018-04-01), US, pages 97 - 105, XP055573246, ISSN: 2159-3337, DOI: 10.1089/nat.2017.0687 *
JEREMIAH J. TRAUSCH ET AL: "Development and Characterization of an HPV Type-16 Specific Modified DNA Aptamer for the Improvement of Potency Assays", ANALYTICAL CHEMISTRY, vol. 89, no. 6, 21 March 2017 (2017-03-21), US, pages 3554 - 3561, XP055573298, ISSN: 0003-2700, DOI: 10.1021/acs.analchem.6b04852 *

Also Published As

Publication number Publication date
IT201800007017A1 (en) 2020-01-06
EP3818160A2 (en) 2021-05-12
WO2020008489A2 (en) 2020-01-09

Similar Documents

Publication Publication Date Title
MX2018015184A (en) Methods for diagnosis of bacterial and viral infections.
MX2019008197A (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFß1 INHIBITORS AND USE THEREOF.
MX2019012534A (en) Combination of elafibranor or derivatives thereof with an anti-nash, anti-fibrotic or anti-cholestatic agent.
PH12017501780A1 (en) Maytansinoid derivatives, conjugates thereof, and methods of use
AU2018263868A1 (en) Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
MX2018002723A (en) Peptidomimetic macrocycles and uses thereof.
MY187540A (en) Compounds active towards bromodomains
WO2016034591A3 (en) Mutant csgg pores
WO2018081648A8 (en) Anti-mic antibodies and methods of use
SG10201808259TA (en) Anti-jagged1 antibodies and methods of use
MX2022008868A (en) Treatment of cancer with tg02.
WO2014138429A3 (en) Peptidomimetic macrocycles and use thereof in regulating hif1alpha
WO2016061456A3 (en) Compositions and methods for identification, assessment, prevention, and treatment of t-cell exhaustion using cd39 biomarkers and modulators
MX2019005401A (en) Methods of treating alport syndrome using bardoxolone methyl or analogs thereof.
MX2020013808A (en) Gremlin-1 antagonist for the prevention and treatment of cancer.
MX2021010886A (en) Medicaments for slowing parkinson's disease.
WO2018136919A3 (en) Methods relating to lung cancer
MX2019015676A (en) Use of isovalerylspiramycin i, ii and/or iii in preparation of drug for treating and/or preventing tumour, and drug.
MA40535A (en) Hsp90-targeted inflammation and infection imaging and therapy
AU201815816S (en) Inhaler
WO2017187343A3 (en) Nanoemulsions and methods for cancer therapy
PH12021550413A1 (en) Vitamin d pediatric dosage forms, methods of making and using
EP3754047A4 (en) Member for use in plasma treatment device, and plasma treatment device provided therewith
MX2021014844A (en) Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function.
MX2023006458A (en) Immunomodulatory oligosaccharides.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19750180

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE